Patents by Inventor Chunhuan JIANG

Chunhuan JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11186587
    Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 30, 2021
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Yazhou Wang, Xu Quan, Chunhuan Jiang, Hongyan Chen, Menghua Chen, Chao Li, Yexin Liao, Qi Liu, Chen Wang, Hai Wang, Shengwei Yang, Guochuang Zheng
  • Patent number: 10961222
    Abstract: Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 30, 2021
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Xiaorong Liu, Yan Zhang, Dandan Huang, Chunhuan Jiang, Xinsheng Shi, Hongfeng Gu, Silin Pang, Wei Hai, Bingyang Ge
  • Publication number: 20200165265
    Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
    Type: Application
    Filed: July 25, 2018
    Publication date: May 28, 2020
    Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong WANG, Liwen ZHAO, Yazhou WANG, Xu QUAN, Chunhuan JIANG, Hongyan CHEN, Menghua CHEN, Chao LI, Yexin LIAO, Qi LIU, Chen WANG, Hai WANG, Shengwei YANG, Guochuang ZHENG
  • Publication number: 20190161473
    Abstract: Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.
    Type: Application
    Filed: July 20, 2017
    Publication date: May 30, 2019
    Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong WANG, Liwen ZHAO, Xiaorong LIU, Yan ZHANG, Dandan HUANG, Chunhuan JIANG, Xinsheng SHI, Hongfeng GU, Silin PANG, Wei HAI, Bingyang GE